Thursday, February 9, 2012 Last update: 1:03 PM
The Best of U.S. Company Technology News
Now being accepted at FreshNews.com. See our complete guidelines.
Trade Events
Biogen Idec
News articles for Biogen Idec:
Monday, January 30, 2012
- Biogen Idec Appoints Kenneth DiPietro Executive Vice President, Human ResourcesBiogen Idec (NASDAQ:BIIB) today announced that Kenneth DiPietro has been named Executive Vice President, Human Resources. Mr. DiPietro will lead the development ... read more
Monday, January 9, 2012
- Biogen Idec Presents 2012 Strategic Priorities at 30th Annual J.P. Morgan Healthcare ConferenceBiogen Idec (NASDAQ: BIIB) will present today its plans for driving the continued strong commercial performance of its existing multiple sclerosis (MS) ... read more
Wednesday, January 4, 2012
- Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular AtrophyBiogen Idec (NASDAQ: BIIB) and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that they have entered into an exclusive, worldwide option and ... read more
Monday, December 5, 2011
- Samsung and Biogen Idec Announce Joint Venture to Develop, Manufacture and Market BiosimilarsSamsung and Biogen Idec (NASDAQ: BIIB) today announced that they have entered into an agreement to invest $300 million to establish a joint venture to ... read more
Wednesday, November 30, 2011
- Biogen Idec to Present at the 2011 Deutsche Bank BioFESTBiogen Idec Inc. (NASDAQ: BIIB) announced today that its presentation at the 2011 Deutsche Bank BioFEST will be webcast live on Tuesday, December 6, 2011 at 8:00 a.m. ... read more
Wednesday, October 26, 2011
- Biogen Idec Announces Positive Top-Line Results from Second Phase 3 Trial Investigating Oral BG-12 (Dimethyl Fumarate) in Multiple SclerosisToday Biogen Idec (NASDAQ: BIIB) announced positive top-line results from CONFIRM, the second of two pivotal Phase 3 clinical trials designed to ... read more
Thursday, October 20, 2011
- Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progression in Define Phase 3 Clinical TrialToday Biogen Idec (NASDAQ: BIIB) announced positive data from the Phase 3 DEFINE clinical trial of oral BG-12 (dimethyl fumarate) in people with ... read more
Wednesday, October 12, 2011
- Data Presented at the 5th Joint Triennial Congress of ECTRIMS and ACTRIMS Demonstrates Biogen Idec’s Novel Science and Commitment to MS PatientsToday Biogen Idec (NASDAQ: BIIB) announced a robust selection of data from the company’s multiple sclerosis (MS) franchise will be presented in 48 ... read more
Friday, September 30, 2011
- More Than 1,000 Biogen Idec Employees across the Globe Help Patients, Communities in First “Care Deeply Volunteer Day”From spending the day with multiple sclerosis patients in Switzerland to cleaning up around a lake in North Carolina to working at the country’s oldest public elementary school ... read more
Thursday, September 29, 2011
- Biogen Idec Promotes Tony Kingsley to Run Global Commercial OperationsBiogen Idec (NASDAQ: BIIB) today announced that Tony Kingsley has been promoted to Executive Vice President, Global Commercial Operations, effective Nov. 7. ... read more
Tuesday, September 6, 2011
- Biogen Idec Fully Acquires Biogen Dompé Joint VenturesBiogen Idec (NASDAQ: BIIB) today announced the company will acquire 100% of Dompé shares in its joint ventures in both Italy and Switzerland. This ... read more
Wednesday, August 31, 2011
- Biogen Idec Announces Webcast of Hemophilia R&D RoundtableBiogen Idec Inc. (NASDAQ: BIIB) announced today that its Hemophilia R&D Roundtable will be webcast live on Monday, September 12, 2011 at 8:00 a.m. ET. To access the ... read more